Ventyx

Ventyx Biosciences is a clinical-stage biopharmaceutical company dedicated to advancing a range of novel small-molecule therapies to develop new treatments for millions of patients with inflammatory and autoimmune diseases. Our clinical-stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of various autoimmune diseases; VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis; and VTX2735, a Phase 1 peripheral inhibitor for the treatment of ulcerative colitis.